Patents – Preventing Access to Medicines

There can be no HIV response without affordable and appropriate medicines for HIV and HIV co-infections

For many years STOPAIDS has successfully campaigned to ensure people living with HIV in the developing world can get the anti-retroviral treatment (ARVs) to stay alive and healthy.

Exponential progress over the past decade now means that there are 15 million people accessing HIV treatment.

The only reason for this progress has been the development of generic production and competition.

Generic production has cut prices for HIV medicines from over $10,000 per patient per year to less than $100 in the past decade.

Generic production is where companies make high quality ‘generic’ copies of drugs created by pharmaceutical companies, and then sell them at a much lower cost.

But these huge gains are now at risk, due to global laws that came into force in India in 2005, called ‘TRIPS’. And further progress is also under threat from so-called Free Trade Agreements (such as TTIP)  and a focus on innovation driven by profit.

As a result second and third line ARVs can still cost over $10,000 per person per year and we are lacking the new medicines we need to treat multi-drug resistant tuberculosis.

Read more about our work on TTIP here and here to explore our efforts to ensure medical research and development produces medicines for people, not profit.

Click here for more information on how you can get involved in STOPAIDS’ upcoming campaign fighting for better access to medicines.

Access to Medicines

Zambia_Lackson-and-his-smiling-mother

Trade

photoTTIP

Innovation

ysa mm